JP2017128614A5 - - Google Patents

Download PDF

Info

Publication number
JP2017128614A5
JP2017128614A5 JP2017091305A JP2017091305A JP2017128614A5 JP 2017128614 A5 JP2017128614 A5 JP 2017128614A5 JP 2017091305 A JP2017091305 A JP 2017091305A JP 2017091305 A JP2017091305 A JP 2017091305A JP 2017128614 A5 JP2017128614 A5 JP 2017128614A5
Authority
JP
Japan
Prior art keywords
release layer
pharmaceutical composition
dibutyl sebacate
magnesium stearate
sustained release
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017091305A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017128614A (ja
JP6325148B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2017128614A publication Critical patent/JP2017128614A/ja
Publication of JP2017128614A5 publication Critical patent/JP2017128614A5/ja
Application granted granted Critical
Publication of JP6325148B2 publication Critical patent/JP6325148B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017091305A 2011-03-23 2017-05-01 注意欠陥障害の処置のための方法および組成物 Active JP6325148B2 (ja)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201161466684P 2011-03-23 2011-03-23
US61/466,684 2011-03-23
US201161561763P 2011-11-18 2011-11-18
US61/561,763 2011-11-18
US201261591129P 2012-01-26 2012-01-26
US61/591,129 2012-01-26

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2016058474A Division JP2016117767A (ja) 2011-03-23 2016-03-23 注意欠陥障害の処置のための方法および組成物

Publications (3)

Publication Number Publication Date
JP2017128614A JP2017128614A (ja) 2017-07-27
JP2017128614A5 true JP2017128614A5 (enExample) 2018-02-08
JP6325148B2 JP6325148B2 (ja) 2018-05-16

Family

ID=46879766

Family Applications (7)

Application Number Title Priority Date Filing Date
JP2014501292A Active JP6043785B2 (ja) 2011-03-23 2012-03-23 注意欠陥障害の処置のための方法および組成物
JP2016058474A Withdrawn JP2016117767A (ja) 2011-03-23 2016-03-23 注意欠陥障害の処置のための方法および組成物
JP2017091305A Active JP6325148B2 (ja) 2011-03-23 2017-05-01 注意欠陥障害の処置のための方法および組成物
JP2018179001A Withdrawn JP2018197276A (ja) 2011-03-23 2018-09-25 注意欠陥障害の処置のための方法および組成物
JP2020035076A Withdrawn JP2020079322A (ja) 2011-03-23 2020-03-02 注意欠陥障害の処置のための方法および組成物
JP2022030878A Withdrawn JP2022066315A (ja) 2011-03-23 2022-03-01 注意欠陥障害の処置のための方法および組成物
JP2023223409A Pending JP2024019726A (ja) 2011-03-23 2023-12-28 注意欠陥障害の処置のための方法および組成物

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2014501292A Active JP6043785B2 (ja) 2011-03-23 2012-03-23 注意欠陥障害の処置のための方法および組成物
JP2016058474A Withdrawn JP2016117767A (ja) 2011-03-23 2016-03-23 注意欠陥障害の処置のための方法および組成物

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2018179001A Withdrawn JP2018197276A (ja) 2011-03-23 2018-09-25 注意欠陥障害の処置のための方法および組成物
JP2020035076A Withdrawn JP2020079322A (ja) 2011-03-23 2020-03-02 注意欠陥障害の処置のための方法および組成物
JP2022030878A Withdrawn JP2022066315A (ja) 2011-03-23 2022-03-01 注意欠陥障害の処置のための方法および組成物
JP2023223409A Pending JP2024019726A (ja) 2011-03-23 2023-12-28 注意欠陥障害の処置のための方法および組成物

Country Status (15)

Country Link
US (1) US9028868B2 (enExample)
EP (4) EP4011364B1 (enExample)
JP (7) JP6043785B2 (enExample)
KR (2) KR20160135373A (enExample)
CN (2) CN103608004A (enExample)
AU (3) AU2012230733B2 (enExample)
BR (1) BR112013024401B1 (enExample)
CA (1) CA2830788C (enExample)
DK (3) DK3272342T3 (enExample)
ES (3) ES2644942T3 (enExample)
MX (4) MX2021000431A (enExample)
PT (3) PT2688557T (enExample)
SG (2) SG10201901167SA (enExample)
WO (1) WO2012129551A1 (enExample)
ZA (1) ZA201307649B (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9119809B2 (en) * 2011-03-23 2015-09-01 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US10905652B2 (en) * 2011-03-23 2021-02-02 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9498447B2 (en) * 2011-03-23 2016-11-22 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US10292937B2 (en) * 2011-03-23 2019-05-21 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
US11241391B2 (en) * 2011-03-23 2022-02-08 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
GB201319791D0 (en) 2013-11-08 2013-12-25 Sigmoid Pharma Ltd Formulations
CA2936740C (en) * 2014-10-31 2017-10-10 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
KR102790656B1 (ko) * 2015-05-04 2025-04-02 컨플루언스 파마슈티컬스, 엘엘씨 아캄프로세이트의 스프링클 제형
PL3324948T3 (pl) * 2015-07-17 2023-06-26 BE Pharbel Manufacturing Wielowarstwowe mikrocząstki uwalniające związek farmaceutycznie aktywny w płynnej postaci dawkowania
US12472149B2 (en) 2015-07-17 2025-11-18 BE Pharbel Manufacturing Multilayered pharmaceutically active compound-releasing microparticles in a liquid dosage form
US10383825B2 (en) 2015-08-13 2019-08-20 Temple University—Of the Commonwealth System of Higher Education Calcium alginate dosage formulations, and methods of making and using thereof
US9849125B1 (en) 2015-11-03 2017-12-26 Banner Lifie Sciences LLC Anti-overingestion dosage forms
WO2017173068A1 (en) * 2016-03-30 2017-10-05 University Of Maryland, Baltimore Microparticulate system for colonic drug delivery
US9827233B1 (en) * 2016-05-26 2017-11-28 Ovid Therapeutics Inc Methods of treating behavioral syndromes using pipradrol
KR102413459B1 (ko) * 2016-07-06 2022-06-24 듀렉트 코퍼레이션 약물 조성물, 장벽 층 및 약물 층을 갖는 경구 투여 형태
US9931303B1 (en) * 2017-02-06 2018-04-03 Alcobra Ltd. Abuse deterrent formulations of amphetamine
US20180256515A1 (en) * 2017-03-10 2018-09-13 Adare Pharmaceuticals, Inc. Oral amphetamine composition
CA3060366A1 (en) * 2017-04-28 2018-11-01 Astellas Pharma Inc. Pharmaceutical composition for oral administration comprising enzalutamide
US12042566B2 (en) 2017-05-17 2024-07-23 Confluence Pharmaceuticals, Llc Formulations of homotaurines and salts thereof
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
EP3459528B1 (en) * 2017-09-20 2022-11-23 Tillotts Pharma Ag Preparation of solid dosage forms comprising antibodies by solution/suspension layering
CN108653243B (zh) * 2018-03-30 2019-03-22 江苏南农高科动物药业有限公司 一种缓释替米考星微囊粉的制备方法
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
EP3662900A1 (en) * 2018-12-07 2020-06-10 Tillotts Pharma AG Colonic drug delivery formulation
EP3662901B1 (en) 2018-12-07 2025-01-01 Tillotts Pharma AG Delayed release drug formulation comprising an outerlayer with an enzymatically degradable polymer, its composition and its method of manufacturing
AU2020212036B2 (en) * 2019-01-25 2025-08-28 Ironshore Pharmaceuticals & Development, Inc. Methylphenidate compositions for treatment of attention deficit hyperactivity disorder

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8322007D0 (en) 1983-08-16 1983-09-21 Wellcome Found Pharmaceutical delivery system
US4904476A (en) 1986-03-04 1990-02-27 American Home Products Corporation Formulations providing three distinct releases
US5474783A (en) 1988-03-04 1995-12-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
WO1990009168A1 (en) 1989-02-16 1990-08-23 National Research Development Corporation Dispensing device
JP2558396B2 (ja) 1990-06-28 1996-11-27 田辺製薬株式会社 放出制御型製剤
US5266331A (en) 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US5656295A (en) 1991-11-27 1997-08-12 Euro-Celtique, S.A. Controlled release oxycodone compositions
US5260068A (en) 1992-05-04 1993-11-09 Anda Sr Pharmaceuticals Inc. Multiparticulate pulsatile drug delivery system
NZ260408A (en) 1993-05-10 1996-05-28 Euro Celtique Sa Controlled release preparation comprising tramadol
JP2916978B2 (ja) 1993-08-25 1999-07-05 エスエス製薬株式会社 放出開始制御型製剤
US5658590A (en) 1995-01-11 1997-08-19 Eli Lilly And Company Treatment of attention-deficit/hyperactivity disorder
IT1276689B1 (it) 1995-06-09 1997-11-03 Applied Pharma Res Forma farmaceutica solida ad uso orale
GB9514451D0 (en) 1995-07-14 1995-09-13 Chiroscience Ltd Sustained-release formulation
US5922736A (en) 1995-12-04 1999-07-13 Celegene Corporation Chronic, bolus administration of D-threo methylphenidate
US6355656B1 (en) 1995-12-04 2002-03-12 Celgene Corporation Phenidate drug formulations having diminished abuse potential
US5837284A (en) 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
US5908850A (en) 1995-12-04 1999-06-01 Celgene Corporation Method of treating attention deficit disorders with d-threo methylphenidate
MX9805870A (enExample) 1996-01-22 1999-01-31
AU715183B2 (en) 1996-02-02 2000-01-20 Medeva Europe Limited Process for the preparation of D-threo-(R,R)-methyl phenidate and recycling of undesired enantiomers by epimerisation
DE69710051T2 (de) 1996-03-08 2002-08-14 Medeva Europe Ltd., Slough Auflösungsverfahren von threo-methylphenidate
GB9606417D0 (en) 1996-03-27 1996-06-05 Chiroscience Ltd Asymmetric cyclisation
DK0932388T5 (da) 1996-09-30 2011-06-27 Alza Corp Doseringsform og fremgangsmåde til indgivelse af lægemidler
US6919373B1 (en) 1996-11-12 2005-07-19 Alza Corporation Methods and devices for providing prolonged drug therapy
EP1782798A3 (en) 1996-11-25 2008-05-21 Alza Corporation Ascending-dose dosage form
DK0946151T3 (da) 1996-11-25 2006-08-28 Alza Corp Doseringsform med stigende dosisfrigivelse
AU7847098A (en) 1996-12-13 1998-07-03 Medeva Europe Limited The preparation of enantiomerically-enriched threo- methylphenidate
GB9700912D0 (en) 1997-01-17 1997-03-05 Chiroscience Ltd Resolution
US6210705B1 (en) 1997-12-15 2001-04-03 Noven Pharmaceuticals, Nc. Compositions and methods for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate
US6524620B2 (en) 1998-07-20 2003-02-25 Andrx Pharmaceuticals, Inc. Diltiazem controlled release formulation and method of manufacture
AU6283299A (en) * 1998-10-01 2000-04-17 Elan Pharma International Limited Controlled release nanoparticulate compositions
US6322819B1 (en) * 1998-10-21 2001-11-27 Shire Laboratories, Inc. Oral pulsed dose drug delivery system
CA2348871C (en) 1998-11-02 2009-04-14 John G. Devane Multiparticulate modified release composition
US6419960B1 (en) 1998-12-17 2002-07-16 Euro-Celtique S.A. Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations
US6733789B1 (en) 1999-01-21 2004-05-11 Biovail Laboratories, Inc. Multiparticulate bisoprolol formulation
US8545880B2 (en) * 1999-02-26 2013-10-01 Andrx Pharmaceuticals, Llc Controlled release oral dosage form
US6384020B1 (en) 1999-07-14 2002-05-07 Shire Laboratories, Inc. Rapid immediate release oral dosage form
US6500459B1 (en) 1999-07-21 2002-12-31 Harinderpal Chhabra Controlled onset and sustained release dosage forms and the preparation thereof
GB9918735D0 (en) * 1999-08-09 1999-10-13 Straken Limited Transdermal patches
US6898455B2 (en) 1999-10-29 2005-05-24 The Mclean Hospital Corporation Method for providing optimal drug dosage
US7108866B1 (en) 1999-12-10 2006-09-19 Biovall Laboratories International Srl Chronotherapeutic diltiazem formulations and the administration thereof
US6569456B2 (en) 2000-01-13 2003-05-27 Osmotica Corp. Osmotic device containing diltiazem and an ACE inhibitor or diuretic
US6627223B2 (en) 2000-02-11 2003-09-30 Eurand Pharmaceuticals Ltd. Timed pulsatile drug delivery systems
US6520921B1 (en) 2000-06-20 2003-02-18 Eastman Kodak Company Method for determining attention deficit hyperactivity disorder (ADHD) medication dosage and for monitoring the effects of (ADHD) medication
US6344215B1 (en) 2000-10-27 2002-02-05 Eurand America, Inc. Methylphenidate modified release formulations
US20030232890A1 (en) 2000-11-01 2003-12-18 Sention, Inc. Methods for treating an impairment in memory consolidation
US6287599B1 (en) 2000-12-20 2001-09-11 Shire Laboratories, Inc. Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
US20040137062A1 (en) 2001-05-25 2004-07-15 Sham Chopra Chronotherapy tablet and methods related thereto
EA005537B1 (ru) 2001-07-10 2005-04-28 Тева Фармасьютикал Индастриес Лтд. Система доставки лекарственного вещества по нулевому порядку, нулевому порядку - двухстадийной, возрастающей или убывающей доставки препарата
US7157103B2 (en) 2001-08-06 2007-01-02 Euro-Celtique S.A. Pharmaceutical formulation containing irritant
US6811794B2 (en) 2001-12-20 2004-11-02 Shire Laboratories, Inc. Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
US7659253B2 (en) 2002-02-22 2010-02-09 Shire Llc Abuse-resistant amphetamine prodrugs
US7700561B2 (en) 2002-02-22 2010-04-20 Shire Llc Abuse-resistant amphetamine prodrugs
US7105486B2 (en) 2002-02-22 2006-09-12 New River Pharmaceuticals Inc. Abuse-resistant amphetamine compounds
US6726624B2 (en) 2002-03-06 2004-04-27 The Mclean Hospital Corporation Method and apparatus for determining attention deficit hyperactivity disorder (adhd) medication dosage and for monitoring the effects of adhd medication on people who have adhd using complementary tests
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
AU2003270349A1 (en) 2002-09-09 2004-03-29 Biovail Laboratories International S.R.L. Chronotherapeutic diltiazem formulations and the administration thereof
US6913768B2 (en) * 2002-09-24 2005-07-05 Shire Laboratories, Inc. Sustained release delivery of amphetamine salts
US7988993B2 (en) 2002-12-09 2011-08-02 Andrx Pharmaceuticals, Inc. Oral controlled release dosage form
EP1589951B1 (en) 2003-01-03 2017-08-09 Supernus Pharmaceuticals, Inc. Use of a mixture of two or more enteric materials to regulate drug release via membrane or matrix for systemic therapeutics
ES2380622T5 (es) 2003-05-29 2018-05-30 Shire Llc Compuestos de anfetamina resistentes al abuso
US20050031688A1 (en) 2003-08-04 2005-02-10 Ayala William J. Positive wakeup pharmaceutical sleep system with compatible pre-bedtime administration
ES2299995T3 (es) 2004-01-29 2008-06-01 Pfizer, Inc. Derivados de 1-isopropil-2-oxo-1,2-dihidropiridina-3-carboxamida con actividad agonista de receptor 5-ht4.
ES2261006B1 (es) * 2004-06-10 2007-11-01 Laboratorios Rubio, S.A. Pellet multicapa de liberacion controlada de metilfenidato.
US20070036843A1 (en) * 2005-01-28 2007-02-15 Collegium Pharmaceutical, Inc. Non-ionic non-aqueous vehicles for topical and oral administration of carrier-complexed active agents
FR2891459B1 (fr) * 2005-09-30 2007-12-28 Flamel Technologies Sa Microparticules a liberation modifiee d'au moins un principe actif et forme galenique orale en comprenant
FR2892937B1 (fr) * 2005-11-10 2013-04-05 Flamel Tech Sa Forme pharmaceutique orale microparticulaire anti-mesusage
MX2008014059A (es) 2006-05-09 2008-11-14 Mallinckrodt Inc Formas de dosificacion solida de liberacion modificada en el orden de cero.
US8846100B2 (en) * 2006-05-12 2014-09-30 Shire Llc Controlled dose drug delivery system
MX2008014455A (es) * 2006-05-12 2008-11-27 Shire Llc Sistema de suministro de farmaco de dosis controlada.
FR2901478B1 (fr) * 2006-05-24 2015-06-05 Flamel Tech Sa Forme pharmaceutique orale multimicroparticulaire a liberation prolongee
CN1985810A (zh) * 2006-07-28 2007-06-27 中国人民解放军第二军医大学 盐酸哌甲酯缓控释胶囊及其制备方法
KR100888131B1 (ko) 2006-10-10 2009-03-11 한올제약주식회사 시간차 투약 원리를 이용한 심혈관계 질환 치료용 복합제제
CN102973942B (zh) 2006-10-30 2015-08-12 韩诺生物制约株式会社 包含血管紧张素II受体阻断剂和HMG-CoA还原酶抑制剂的控释复合组合物
CN103120653B (zh) 2007-04-04 2015-09-30 希格默伊德药业有限公司 一种口服药物组合物
US8318813B2 (en) 2007-09-13 2012-11-27 Lcs Group, Llc Method of treating binge eating disorder
AU2009207796B2 (en) * 2008-01-25 2014-03-27 Grunenthal Gmbh Pharmaceutical dosage form
CA2627198A1 (en) 2008-03-27 2009-09-27 Pharmascience Inc. Methylphenidate extended release therapeutic drug delivery system
WO2011041414A1 (en) 2009-09-30 2011-04-07 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse

Similar Documents

Publication Publication Date Title
JP2017128614A5 (enExample)
JP2017019858A5 (enExample)
US11903908B2 (en) Methods of administering amantadine
FI3287124T3 (fi) Ketamiinin oraalinen annosmuoto
US11975103B2 (en) Compositions of midodrine and methods of using the same
JP2014508812A5 (enExample)
JP2011509295A5 (enExample)
JP2016117767A5 (enExample)
US20210220281A1 (en) Oral pharmaceutical compositions of mesalazine
JP2016516698A5 (enExample)
JP2009215293A5 (enExample)
JP2013512919A5 (enExample)
JP2011510024A5 (enExample)
HUE035830T2 (en) New combination
JP2021506944A (ja) 持続放出ミドドリン塩酸塩組成物及び使用方法
WO2005055955B1 (en) DOSING METHODS FOR ß-D-2’,3’-DIDEOXY-2’,3’-DIDEHYDRO-5-FLUOROCYTIDINE ANTIVIRAL THERAPY
US20110033506A1 (en) Combination dosage form of low-dose modafinil and low-dose sildenafil
TWI508755B (zh) 供三甲氧苄嗪（ｔｒｉｍｅｔａｚｉｄｉｎｅ）延長釋放之醫藥組合物
US11622938B2 (en) Oral pharmaceutical compositions of nicotinamide
JP2021001190A (ja) トリパルス放出型賦活薬製剤
JP2015506980A5 (enExample)
AU2018286535B2 (en) Delayed sustained release pharmaceutical compositions
US20200054659A1 (en) Extended release capecitabine capsules
JP2018502168A5 (enExample)
JP2017515858A5 (enExample)